RxDoctor Payments DataLook up a doctor →

N Charle Morcos

Cardiovascular Disease · Santa Ana, CANPI 1285656835

Payments from drug & device makers

$696,589in general payments, 2019–2025

Across 333 payments — averaging $2091.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$298K
  • Novartis$207K
  • Janssen Research & Development, LLC$135K
  • Chiesi USA, Inc.$19K
  • AstraZeneca$16K
  • Pfizer$14K
  • plus $8K from 15 others

What the payments were for

  • Food & beverage$2,883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$696,589 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$277,276
Medicare patients
366
Services billed
3,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$129,471
FarxigaDapagliflozin Propanediol43$34,758
XareltoRivaroxaban22$25,482
Repatha SureclickEvolocumab26$18,135
JanuviaSitagliptin Phosphate16$15,136
JardianceEmpagliflozin13$14,079
EntrestoSacubitril/Valsartan13$14,072
Metoprolol Succinate247$3,757
Losartan Potassium187$2,228
Rosuvastatin Calcium135$2,095
Atorvastatin Calcium161$1,875
Amlodipine Besylate161$1,691
Flecainide Acetate50$1,632
Potassium Chloride28$1,072
Spironolactone131$1,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13,533$129,471144 claims
AstraZenecaFarxiga$15,545$34,75843 claims
Johnson & JohnsonXarelto$87$25,48222 claims
MerckJanuvia$337$15,13616 claims
Boehringer IngelheimJardiance$97$14,07913 claims
NovartisEntresto$207,183$14,07213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →